AE36 HER2/neu-derived peptide linked to positively charged liposomes with CpG-ODN as an effective therapeutic and prophylactic vaccine for breast cancer

In the present day and age, cancer is still a life-limiting factor whose one of the therapeutic strategies is immunotherapy with vaccines. This research aims to prepare and characterize nanoliposomal vaccine formu-lation attached to HER2/neu-derived peptide (AE36) with or without CpG-ODN, and to evaluate its immuno-logical responses to the therapy using BALB/c mice with HER2 overexpressing breast cancer. AE36 was conjugated to the liposomes containing DOTAP, DOPE and Cholesterol. Such formulations are able to produce CD8(+) and CD4(+) responses and induce synthesis of cytokines detectable via Enzyme-linked immunosorbent assay kits, cytotoxicity testing and intracellular cytokine staining combine.

Automated summary

The study focuses on developing a nanoliposomal vaccine for HER2-overexpressing breast cancer to evaluate its immunotherapeutic effects. The findings demonstrate that the formulation is capable of eliciting CD8(+) and CD4(+) responses, inducing the synthesis of cytokines.